Guru Sonpavde

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

Guru Sonpavde
Jun 12, 2025, 08:47 | Blog
Guru Sonpavde: Genitourinary Medical Oncology Highlights From ASCO Annual Conference 2025
Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research…
May 25, 2025, 16:16 | Blog
Guru Sonpavde: Role of Adjuvant Therapy in Current Perioperative Immunotherapy-Based Trials in Bladder Cancer
Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research…
May 21, 2025, 16:57 | Science
Guru Sonpavde: CheckMate 901 Trial Data on First-Line Nivolumab in LN-Only Metastatic Urothelial Carcinoma
Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research…
May 10, 2025, 12:49 | Blog
Guru Sonpavde: New Study on Early Dynamics of Atezolizumab Resistance in Systemic Immunotherapy for Bladder Cancer
Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research…
May 2, 2025, 08:14 | Insight
Guru Sonpavde: Cabozantinib Plus PD1 Inhibition Immunotherapy Active
Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research…
Mar 30, 2025, 13:24 | Blog
CPOEM Foundation - Thrilled to share the recording of ASCO-Endorsed CPOEM Foundation Webinar
CPOEM Foundation posted on LinkedIn: "Webinar Recording Available! We are thrilled to share the recording…
Mar 27, 2025, 13:57 | Blog
Jasmine Kamboj: Access to oncological drugs and clinical trials - US vs LMICs
Jasmine Kamboj, Medical Oncologist and Hematologist at Mayo Clinic, shared a post on LinkedIn: "Please…
Mar 26, 2025, 01:41 | Blog
Inside MaTOS GU25: Insights from Chandler Park part 2
The Masters in Therapeutic Oncology Summit – Genitourinary (GU) Edition (MaTOS GU25) brought together some…
Feb 10, 2025, 16:11 | Blog
Guru Sonpavde: Take home messages from Puerto Rico Oncology Symposium
Guru Sonpavde, Phase I Clinical Trials Director at Advent Health Central Florida and the Chair…
Feb 4, 2025, 16:23 | Blog
Guru Sonpavde: Current therapy and recent advances in bladder cancer treatment at APPOS25
Guru Sonpavde, Phase I Clinical Trials Director at Advent Health Central Florida and the Chair…
Feb 2, 2025, 17:00 | Insight
Guru Sonpavde: Exciting trials to look for at ASCO GU25
Guru Sonpavde, Phase I Clinical Trials Director at Advent Health Central Florida and the Chair of…
Jan 6, 2025, 12:15 | Insight
Erman Akkus: Adjuvant pembrolizumab after surgery in high risk muscle invasive bladder cancer
Erman Akkus, Medical Oncology fellow at Ankara University, Faculty of Medicine, shared a post on…
Jan 3, 2025, 21:19 | Insight
Advancements in urothelial carcinoma treatment - International Urology Cancer Summit
International Urology Cancer Summit shared a post on LinkedIn: "Advancements in urothelial carcinoma treatment. The latest…
Dec 24, 2024, 13:12 | Blog
Guru Sonpavde: Phase I clinical trial unit update from Advent Health Central Florida Cancer Institute
Guru Sonpavde, Phase I Clinical Trials Director at Advent Health Central Florida and the Chair…
Dec 2, 2024, 13:05 | Career
Guru Sonpavde: Job opportunity for a medical oncologist to join AdventHealth Central Florida's GU Program
Guru Sonpavde, Oncology and Phase I Clinical Trials Director at AdventHealth Central Florida, shared a…
Nov 5, 2024, 17:59 | Insight
Guru Sonpavde: Meta-analysis of adjuvant PD1/L1 inhibitor immunotherapy in MIBC
Guru Sonpavde, Oncology and Phase I Clinical Trials Director at AdventHealth Central Florida, shared a…
Oct 31, 2024, 17:06 | Blog
Sarah Louden: The latest insights and breakthroughs from the ESMO USA East meeting
Sarah Louden, Founder and CEO at Total Health Oncology, shared on LinkedIn: ''ESMO USA East…
Oct 29, 2024, 12:13 | Blog
OncoInfluencers to Follow on Social Media: Dr. Guru Sonpavde
We’re pleased to feature Dr. Guru Sonpavde, a leader in drug development and genitourinary oncology,…
Oct 29, 2024, 10:29 | Blog
Guru Sonpavde: Pleased to discuss bladder cancer highlights at ESMO East conference
Guru Sonpavde posted on LinkedIn: "ESMO24 bladder cancer highlights: Pleased to discuss from AdventHealth Central…
Oct 21, 2024, 19:19 | Blog
Guru Sonpavde: Potentially practice-changing highlights from 2 key Phase III clinical trials
Guru Sonpavde shared a post on LinkedIn: ''ESMO24 bladder cancer potentially practice-changing highlights from 2…
Oct 19, 2024, 16:37 | Drugs
Gilead Sciences has voluntarily withdrawn Trodelvy from the U.S. market
Gilead Sciences announced the voluntary withdrawal of its drug Trodelvy for bladder cancer after it…
Sep 24, 2024, 17:11 | Blog
Guru Sonpavde: ESMO24 bladder cancer highlight HRQoL outcomes from CheckMate 901 trial
Guru Sonpavde shared a post on LinkedIn: "ESMO24 bladder cancer highlight: Health-related quality of life (HRQoL)…
Sep 24, 2024, 12:30 | Societies
11 ESMO24 presentations published on NEJM
At the 2024 ESMO Congress, 11 articles were presented that were published in NEJM, highlighting…
Sep 23, 2024, 15:50 | Insight
Guru Sonpavde: ESMO24 bladder cancer practice-changing highlight
Guru Sonpavde, Genitourinary Oncology and Phase I Clinical Trials Director of Chair of Bladder Cancer…
Sep 21, 2024, 13:04 | Blog
Guru Sonpavde: Adjuvant pembrolizumab improved outcomes in MIBC
Guru Sonpavde, Genitourinary Oncology and Phase I Clinical Trials Director of Chair of Bladder Cancer…
Sep 15, 2024, 12:53 | Blog
Sumanta Pal's highlights from ESMO24
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…
Jul 24, 2024, 13:13 | Blog
Earle Burgess: Bipolar androgen therapy for advanced prostate cancer
Earle Burgess, Genitourinary Medical Oncologist, Atrium Health Levine Cancer Institute, shared on LinkedIn: "Bipolar androgen therapy…
Jun 26, 2024, 10:24 | Blog
Chandler Park: Which patients would you not give EV-Pembro for 1st line metastatic bladder cancer?
Chandler Park shared on X:               . "Which patients would…
Jun 22, 2024, 02:24 | Insight
Guru Sonpavde: ctDNA for Evaluating Minimal Residual Disease in Bladder Cancer
Guru Sonpavde, Phase I and GU Oncology Director at Advent Health Cancer Institute, posted on…
May 4, 2024, 12:13 | Insight
New Paper Alert! Understanding MSI and MMR in Urothelial Carcinoma: Systematic Review and Meta-analysis
Understanding MSI & MMR in Urothelial Carcinoma: Systematic Review and Meta-analysis Authors: Elias B A…
May 2, 2024, 10:16 | Blog
Matthew Kurian: Had a fantastic time at PrecisCa 2024
Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine, shared…
Apr 11, 2024, 11:56 | Blog
Guru P. Sonpavde: AACR⁩ - Many promising options for Phase I clinical trials
Guru P. Sonpavde, GU Oncology Director at Advent Health Cancer Institute, shared on X/Twitter: "AACR24 ⁦AACR⁩…
Mar 6, 2024, 10:51 | Blog
Guru Sonpavde: Phase I clinical trial early drug development update from AdventHealth Central Florida
Guru Sonpavde, Medical Director at the AdventHealth Cancer Institute, shared a post on LinkedIn: "Phase I clinical…
Nov 21, 2023, 13:57 | Blog
Vivek Subbiah: Honored to co-author with brilliant "Guru" of bladder cancer Guru Sonpavde.
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a…
All: 34 Posts: 1 - 100
Special Coverage